Is the Delphi's Oracle Pertinent to Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? - Reply

J. Annelie Suurmeijer; Marc G. Besselink; Hanneke W. M. van Laarhoven

doi:https://doi.org/10.1001/jamaoncol.2022.4676

Is the Delphi's Oracle Pertinent to Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? - Reply

J. Annelie Suurmeijer, Marc G. Besselink, Hanneke W. M. van Laarhoven

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	1851-1852
Number of pages	2
Journal	JAMA Oncology
Volume	8
Issue number	12
Early online date	2022
DOIs	https://doi.org/10.1001/jamaoncol.2022.4676
Publication status	Published - 15 Dec 2022

Access to Document

https://doi.org/10.1001/jamaoncol.2022.4676

Cite this

@article{c1ab38e6742b42989bf1366dd4f5edab,

title = "Is the Delphi's Oracle Pertinent to Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? - Reply",

author = "Suurmeijer, {J. Annelie} and Besselink, {Marc G.} and {van Laarhoven}, {Hanneke W. M.}",

note = "Funding Information: funding from Pfizer outside the submitted work. Dr R{\o}der reported serving on advisory boards for Astellas Pharma, Pfizer, Janssen-Cilag, Bayer, and MSD outside the submitted work. No other disclosures were reported.",

year = "2022",

month = dec,

day = "15",

doi = "https://doi.org/10.1001/jamaoncol.2022.4676",

language = "English",

volume = "8",

pages = "1851--1852",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "12",

}

TY - JOUR

T1 - Is the Delphi's Oracle Pertinent to Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? - Reply

AU - Suurmeijer, J. Annelie

AU - Besselink, Marc G.

AU - van Laarhoven, Hanneke W. M.

N1 - Funding Information: funding from Pfizer outside the submitted work. Dr Røder reported serving on advisory boards for Astellas Pharma, Pfizer, Janssen-Cilag, Bayer, and MSD outside the submitted work. No other disclosures were reported.

PY - 2022/12/15

Y1 - 2022/12/15

UR - http://www.scopus.com/inward/record.url?scp=85140487894&partnerID=8YFLogxK

U2 - https://doi.org/10.1001/jamaoncol.2022.4676

DO - https://doi.org/10.1001/jamaoncol.2022.4676

M3 - Comment/Letter to the editor

C2 - 36201220

SN - 2374-2437

VL - 8

SP - 1851

EP - 1852

JO - JAMA Oncology

JF - JAMA Oncology

IS - 12

ER -

Is the Delphi's Oracle Pertinent to Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? - Reply

Access to Document

Other files and links

Cite this